Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Meyenburg Cancer Research Award 2007 given to Dr. Shinya Yamanaka for the artificial generation of stem cells

No. 72 | 23/11/2007

The Meyenburg Cancer Research Award 2007 accompanied by Euro 50,000 ($ 75,000) in prize money has been presented to the renowned Japanese stem cell expert, Dr. Shinya Yamanaka. Yamanaka has succeeded in endowing normal skin cells with almost every characteristic of an embryonic stem cell. Great hopes are being set on the use of these induced embryonic stem cells in cancer treatment and transplantation medicine. The award has been presented within the framework of a scientific symposium on stem cell biology in the German Cancer Research Center (DKFZ) on Monday, November 26, 2007.

Stem cells have significant potential for bringing advances to many fields of medical science. They could, for example, replace the insulin producing cells lacking in diabetes, compensate the lack of dopamine in patients with Parkinson’s disease and substitute cardiac muscle cells which have been destroyed by a heart attack.

However, physicians face a dilemma in their attempts to develop new therapeutic approaches based on using stem cells: stem cells taken from a mature organism are not well suited for use in many forms of medical therapy. They do not possess the quality called "pluripotency" which enables them to to give rise to different types of tissues in the human body. For a long time the only cells with this capability were embryonic stem cells isolated out of cells in a very early stage of embryo development called blastocyst.

The pioneering work performed by Shinya Yamanaka brings the efforts to produce pluripotent stem cells without using embryonic tissue a significant step forward. Last year, Yamanaka was the first researcher to successfully reprogram cells from normal connective tissue taken from the skin of a mouse back into stem cells. By transferring only four genes, the skin fibroblast cells were transformed into cells with characteristics very similar to those of stem cells. An article by the Japanese researcher in the scientific journal "Cell" just this week describes how cells from human connective tissue can be programmed back into embryonic stem cells, an achievement which attracted much attention from scientists and the general public in the last few days.

Yamanaka’s results are also of great significance for cancer research: when the cells of the human body become cancerous, biological programs are reactivated that might be very similar to the process Yamanaka’s group induced by their gene transfer. By decoding this program, scientists will learn more precisely where to interfere with the mechanisms which lead to malignant cell growth, and how to counteract this fatal process.

As a tribute to the awardee, the German Cancer Research Center has organized a symposium featuring some of the most well-known experts in the field of stem cell research. Ken Chien is one of the world’s leading experts on the programming of stem cells to cardiac muscles, Andreas Schoeler and Christof Niehrs are prominent specialists on the regulation of stem cells, Ron McKay is considered to be one of the most important expert on the development of stem cell-based treatment for Parkinson’s disease and Andreas Trumpp discovered a central mechanism which stem cells use to self-renew.

More than 400 attendees watched as Dr. Marion Meyenburg, the daughter of the founders of the Meyenburg foundation, Wilhelm and Maria Meyenburg, has presented the award to Shinya Yamanaka at the end of the symposium. This distinction has been awarded for outstanding achievements in cancer research annually since 1981 and is one of the most well-funded scientific awards in Germany.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS